Answers are grounded in this paper and cite their sources.
Since the invention of polymerase chain reaction in 1983, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) has been regarded as a gold standard for measuring mRNA abundance in cells and tissues.1 Because qRT-PCR measures of mRNA abundance are relative, stable endogenous reference genes (internal control genes [ICGs]) are required to normalise gene expression in biological samples. An important characteristic of ICGs is that their expression remains unchanged by other factors such as drugs and other experimental treatments.2 Changes in stability of ICGs, especially during experimental treatments, produce fallacious results and lead to errors in interpreting gene expression data.3 Tricarico et al.4 suggested that no ICGs are stable enough to be suitable for use with human skin biopsy samples, yet many papers, based on studies of human or animal dermal fibroblasts and tissues, have been published without considering the stability of ICGs used in those studies. In dermal fibrosis and wound-healing studies, 18s and/or GAPDH have been the ICGs of choice. However, to the best of our knowledge, the stability of these and other ICGs has not been tested using a range of cultured human fibroblasts except for GAPDH in a study of human fibroblasts from the same patient to avoid biological variation.5 Based on previous publications, we selected 10 ICGs; three commonly used genes [18s, ACTB and GAPDH] and seven less common genes [RPLP0, β2M, PGK, RPL32, EEF1A1, PPIA and MRPL19] (see Supplementary Materials). Our aim was to identify suitable stable ICGs for use in quantifying mRNA transcripts of fibrosis-related genes in untreated and treated primary cultures of human dermal fibroblasts. After primers were validated, we proceeded to characterise the gene expression of these ICGs in cultured human fibroblasts from healthy volunteers and keloid patients. These samples were tested with and without activin treatment and were performed using qRT-PCR. (Supplementary Materials for detailed information). The relative gene expression of ICGs was measured and demonstrated by threshold cycles which represent concentrations of target genes in the PCR reaction (Fig. 1). As two widely used ICGs, GAPDH and ACTB, have been reported as unstable reference genes in the presence of serum,6 our fibroblast cultures were serum-starved for 24 hours prior to any experiments; this removed the need to test for serum-mediated variations. Based on our results, GAPDH was more stable than ACTB and 18s (Fig. 1) and ACTB showed variable basal gene expression sufficient to disqualify it as a suitable ICG. Although 18s was stably expressed under basal conditions in this study, and that of Schmittgen and Zakrajsek,6 significant variation in 18s gene expression was observed when we treated fibroblasts with activin. For this reason, 18s is not recommended as an ICG for activin and TGFβ superfamily-related studies. These results explain the low stability ranking given to ACTB and 18s in this study (Table S4, Supplementary Materials). The seven less commonly used ICGs that we tested for gene expression stability provided the two most stable reference genes (PGK and MRLP19) for use with human dermal fibroblasts with and without activin treatment (Fig. 1 and Fig. S3 for RPLP0 and PPIA). The remaining five genes showed sufficient instability to exclude them from selection as ICGs for fibroblast gene expression studies. For example, although β2M and PPIA were rated the most stable ICGs in colorectal cancer studies,7 our results indicated that these two genes were variably expressed under basal conditions in dermal fibroblasts, which significantly compromised interpretation of the data. EEF1A1 also showed differential expression under basal conditions that was sufficient to exclude it from selection. Interestingly, β2M, PPIA and EEF1A1 all showed stable expression in fibroblasts under activin treatment (Fig. 1 and Fig. S3). However, because our experimental protocols require reference gene stability across different dermal fibroblast samples from various skin diseases, β2M, PPIA and EEF1A1 were not reliable enough for selection. In previous gene expression studies, RPLP0 and RPLP32 have been used successfully as ICGs.8, 9 However, in our study, although RP-mRNA gene expression levels were less variable between untreated and activin-treated samples, basal gene expression of these genes showed large variations between patient samples which rendered them unsuitable for gene expression studies of human dermal fibroblasts. Previously, Kheirelseid et al.7 concluded that, except for the combination of β2M and PPIA, MRPL19 was the most stable ICG in colorectal cancer. Our results showed that MRPL19 was also a stable ICG in human fibroblasts both with and without activin treatment but had the disadvantage of relatively low abundance. In contrast, PGK was not only stable under all experimental conditions but was also present in high abundance (Fig. 1). This is consistent with our ranking analysis using NormFinder software that showed MRPL19 and PGK ranked 1st and 2nd, respectively, with and without treatment. To validate stable ICGs, TP53 gene expression was compare between human fibroblasts using MRPL19 and the two commonly used ICGs: GAPDH and ACTB (Fig. 2). Although cDNA synthesis was performed using same total amount of RNA, basal TP53 gene expression varied significantly between samples (Fig. 2a). Normalisation experiments for TP53 gene expression using the three selected ICGs showed variation in the gene expression pattern for TP53 between the three ICGs. The expression profile for GAPDH was similar to TP53 gene expression without normalisation. However, after fibroblasts were stimulated with activin A, TP53 varied between samples after normalisation with GAPDH (Fig. 2b). Normalisation with ACTB also showed high levels of variation between samples but with lower expression of TP53 in the keloid samples (Fig. 2c). Of the three ICGs tested, MRPL19 showed the least variation in TP53 gene expression between samples before and after activin A treatment (Fig. 2d) confirming its selection for use in gene expression studies with dermal fibroblasts. Of the 10 IGCs tested, PGK and MRPL19 were the highest rating selections and are recommended as stable and reliable ICGs for measuring gene expression changes in experiments using human dermal fibroblasts. SH performed the research, contributed to data analysis and wrote the manuscript. GS provided human patient samples. PTS designed the project and contributed to data analysis. CH, GS and PTS contributed to manuscript drafting and supervision. This research was supported by funding from the Advanced Plastic Surgery Education Foundation (Australia). SH is a recipient of Monash International Postgraduate Research Scholarship and Monash Graduate Scholarship (Australia). The authors declare that there is no conflict of interest. Data S1 Supplemenatary materials & methods Data S2 Supplementary references Table S1 Clinical Characteristics of subjects Table S2 Primer-specific amplification efficiencies Table S3 Primer sequences and size of qRT-PCR products Table S4 Ranking of internal control genes Figure S1 Agarose gel electrophoresis of qRT-PCR products from 10 selected internal control genes Figure S2 Dissociation curve analysis of primer-specific amplification Figure S3 Relative mRNA expression of RPLP0 and PPIA genes in human dermal fibroblasts Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Ham et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: